Results 31 to 40 of about 289,858 (293)

Checkpoint Blockade in Cancer Immunotherapy [PDF]

, 2006
The progression of a productive immune response requires that a number of immunological checkpoints be passed. Passage may require the presence of excitatory costimulatory signals or the avoidance of negative or coinhibitory signals, which act to dampen or terminate immune activity.
Alan J, Korman, Karl S, Peggs, James P, Allison   +2 more
openaire   +2 more sources

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma

Frontiers in Oncology, 2019
Currently, the blockade of certain immune checkpoints such as the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1) using checkpoint inhibitors is standard of care in patients with metastatic melanoma, especially ...
Jan-Michael Werner, Viola Schweinsberg, Michael Schroeter, Michael Schroeter, Boris von Reutern, Michael P. Malter, Max Schlaak, Max Schlaak, Gereon R. Fink, Gereon R. Fink, Cornelia Mauch, Cornelia Mauch, Norbert Galldiks, Norbert Galldiks, Norbert Galldiks   +14 more
doaj   +1 more source

G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma

, 2021
Purpose:G9a histone methyltransferase exerts oncogenic effects in several tumor types and its inhibition promotes anticancer effects. However, the impact on checkpoint inhibitor blockade response and the utility of G9a or its target genes as a biomarker ...
Kamal, Nabilah Ahmad, Gannon, Frank, Lee, Jason S., Wilmott, James S., Ferguson, Blake, Silva, Ines P., Al-Ejeh, Fares, Rao, Sudha, McCuaig, Robert, Pritchard, Antonia L., Long, Georgina, V, Ali, Sayed, Scolyer, Richard A., Hayward, Nicholas K., Kelly, Gregory M., Casciello, Francesco   +15 more
core   +1 more source

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment

Frontiers in Immunology, 2020
Advances in cancer immunity have promoted a major breakthrough in the field of cancer therapy. This is mainly associated with the successful development of immune checkpoint inhibitors (ICIs) for multiple types of human tumors.
Yuxiao Song, Yang Fu, Qi Xie, Bo Zhu, Jun Wang, Bicheng Zhang   +5 more
doaj   +1 more source

Cancer Immunotherapy: Beyond Checkpoint Blockade [PDF]

Annual Review of Cancer Biology, 2019
Blocking antibodies to the immune checkpoint receptors or their ligands have revolutionized the treatment of diverse malignancies. Many tumors are recognized by adaptive immunity, but these adaptive responses can be inhibited by immunosuppressive mechanisms within the tumor, often through pathways outside of the currently targeted checkpoints.
Michael, Dougan, Glenn, Dranoff, Stephanie K, Dougan   +2 more
openaire   +2 more sources

Tumour-intrinsic resistance to immune checkpoint blockade [PDF]

, 2020
'Immune checkpoint blockade' for cancer describes the use of therapeutic antibodies that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour immune responses.
Antoni Ribas, Anusha Kalbasi, Kalbasi, Anusha, Ribas, Antoni   +3 more
core   +1 more source

Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer

Neoplasia: An International Journal for Oncology Research, 2019
Immune checkpoint inhibitors have shown clinical benefit in several cancer entities including metastatic microsatellite instable colorectal carcinomas. However, for the majority of metastatic colorectal carcinomas the potential and limitations of immune ...
E Fiegle, D Doleschel, S Koletnik, A Rix, R Weiskirchen, E Borkham-Kamphorst, F Kiessling, W Lederle   +7 more
doaj   +1 more source

Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model

Frontiers in Oncology, 2020
Despite the success of immune checkpoint blockade in cancer, the number of patients that benefit from this revolutionary treatment option remains low.
Evelyn Sirait-Fischer, Catherine Olesch, Annika F. Fink, Matthias Berkefeld, Arnaud Huard, Tobias Schmid, Kazuhiko Takeda, Bernhard Brüne, Bernhard Brüne, Bernhard Brüne, Bernhard Brüne, Andreas Weigert, Andreas Weigert, Andreas Weigert   +13 more
doaj   +1 more source

Metabolic Implications of Immune Checkpoint Proteins in Cancer

Cells, 2022
Expression of immune checkpoint proteins restrict immunosurveillance in the tumor microenvironment; thus, FDA-approved checkpoint inhibitor drugs, specifically PD-1/PD-L1 and CTLA-4 inhibitors, promote a cytotoxic antitumor immune response.
Elizabeth R. Stirling, Steven M. Bronson, Jessica D. Mackert, Katherine L. Cook, Pierre L. Triozzi, David R. Soto-Pantoja   +5 more
doaj   +1 more source

PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma

Cells, 2021
The dependence of cancer on an immunotolerant tumor microenvironment (TME) is well established. Immunotherapies that overcome tumor-induced immune suppression have been central to recent advancements in oncology.
Joshua W. D. Tobin, Karolina Bednarska, Ashlea Campbell, Colm Keane   +3 more
doaj   +1 more source